Navigation Links
Ocera Therapeutics Presents Data on AST-120 in Patients With Hepatic Encephalopathy at the European Association for the Study of Liver Disease Annual Meeting
Date:4/28/2009

The Company also Initiates the Phase 2b ASTUTE Clinical Trial for Mild Hepatic Encephalopathy

SAN DIEGO, April 28 /PRNewswire/ -- Ocera Therapeutics, Inc., a privately held biopharmaceutical company, announced that data from its phase 2 study of AST-120 for the treatment of patients with low-grade hepatic encephalopathy was presented April 25th at the 44th Annual Meeting of the European Association for the Study of Liver Disease (EASL) in Copenhagen. The study showed that AST-120 was better tolerated than lactulose, the standard of care in this population, with similar overall efficacy. An improvement on neurocognitive measures was also seen with AST-120. Based on these positive data, Ocera has initiated and dosed their first patient in the ASTUTE study, a phase 2b study of AST-120 in patients with mild hepatic encephalopathy (MHE).

The phase 2a study randomly assigned 47 patients with West Haven Scale (WHS) Grade 1-2 hepatic encephalopathy to 4 weeks of treatment with either AST-120 2g sachets (A) QID or lactulose (L) titrated to bowel movements. Forty-one patients were evaluable (n=21 A, 20 L) and 6 were excluded (n=3 L: non-compliance, n=3 A: other causes). Treatment response by WHS at Week 4 was similar between treatment groups (38.1% vs. 35.0%, A vs. L). AST-120 also produced an improvement in neurocognitive measures. A statistically significant reduction in pruritus, a secondary endpoint of the trial, was seen with AST-120 compared to lactulose. Adverse events related to diarrhea (p = 0.04) and flatulence (p = 0.02) were significantly less in patients treated with AST-120.

The improvement seen in neurocognitive measures is consistent with reports that neuropsychometric testing is required to truly measure deficits and detect changes in neurocognitive functioning in the MHE patient population.

"Patients with mild hepatic encephalopathy often don't comply with lactulose therapy because
'/>"/>

SOURCE Ocera Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Ocera Therapeutics Announces Positive Results with AST-120 in Pouchitis
2. Ocera Therapeutics Closes $35.5 Million Series C Financing
3. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer
4. Sir Richard Sykes Joins BioCeramic Therapeutics as Chairman
5. Dr Stephan Rietiker Joins BioCeramic Therapeutics
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... OAKS, Calif. , Feb. 26, 2015 ... achieved Gold Partner status in Oracle PartnerNetwork. In attaining ... for its commitment to establish Oracle-related knowledge in delivering ... the challenges of joint customers. Originally developed ... researchers to rapidly zoom in and out of massive ...
(Date:2/26/2015)... Feb. 26, 2015  Epic Sciences announced today that ... present at the 35th Annual Cowen and Company Health ... the MIT Room, 3rd Floor. The conference will be ... Mass. Epic is developing diagnostic tests of ... and proteomic changes that occur during the course of ...
(Date:2/26/2015)... -- Spark Therapeutics (NASDAQ: ONCE ) announced today ... the Cowen and Company Health Care Conference on Wednesday, ... Boston Marriott Copley Place. To access the ... Cowen conference, please visit the "Upcoming Events" section within ... website at www.sparktx.com .  A replay of the ...
(Date:2/26/2015)... York (PRWEB) February 26, 2015 On ... dedicated to building a nationwide Clostridium difficile (C. diff) ... C. diff burden study by the Centers for Disease ... diff caused almost half a million infections among Americans ... U.S. nursing homes. , The study also estimates ...
Breaking Biology Technology:Ceres Becomes Oracle PartnerNetwork Gold Level Partner 2Ceres Becomes Oracle PartnerNetwork Gold Level Partner 3Ceres Becomes Oracle PartnerNetwork Gold Level Partner 4Epic Sciences to Present at 35th Annual Cowen and Company Health Care Conference 2Spark Therapeutics to Participate in the 35th Annual Cowen and Company Health Care Conference 2Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 2Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 3Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 4
... Monday, January 28, The Royal,Marsden Hospital (Sutton, ... Arc Therapy (VMAT)* treatment in the world ... treatment, the hospital,used its existing Elekta Synergy(R) ... system., (Logo: http://www.newscom.com/cgi-bin/prnh/20020318/ELEKTALOGO ), ...
... Caliper Life,Sciences, Inc. (Nasdaq: CALP ) ... 2008 Small and Mid Cap Growth Conference in ... at 4:40 p.m. EST. Kevin,Hrusovsky, President and CEO ... the,company,s business. The live webcast can be accessed ...
... Germany and MINNEAPOLIS, Minnesota, February 11, Bayer HealthCare ... Minneapolis, MN, (Nasdaq: POSS ), announced today ... pursuant to which,MEDRAD will acquire Possis Medical in ... or a total equity value of approximately US-Dollar ...
Cached Biology Technology:Elekta Announces First Volumetric Modulated Arc Therapy Cancer Treatment at Royal Marsden Hospital 2Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 2Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 3Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 4Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 5Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 6
(Date:2/25/2015)... Ark. , Feb. 25, 2015  ABC ... and billing in the Health and Fitness Industry, ... well as to MYiCLUBonline.  The latest upgrade includes ... the inclusion of cardless check-in via Identity One ... the first time through interactive displays at the ...
(Date:2/24/2015)... This report analyzes the worldwide markets for Iris Biometrics in ... US, Canada , Japan ... , Middle East , and ... for the period 2013 through 2020. Also, a seven-year historic ... are derived from primary and secondary research. Company profiles are ...
(Date:2/24/2015)... NEW YORK , Feb. 24, 2015 This report ... Thousands by the following Segments: Face Biometrics, and Voice Biometrics. The ... , Japan , Europe ... & Africa , and Latin ... period 2013 through 2020. Also, a seven-year historic analysis is provided ...
Breaking Biology News(10 mins):ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16
... old, have been ill, or suffered an injury, you,ve watched ... slight or gradualis about as common to the human condition ... little about what causes skeletal muscles to atrophy. They know ... and parsing the key actors from the poseurs is tricky. ...
... A broken chromosome is like an unmoored beansprout circling in ... with broken chromosomes, the cell will be killed and so ... Often, it finds a workable substitute: another nearby chromosome. When ... a similar process to exchange genetic material, you,ve got a ...
... found a way to replace up to 50 per cent ... Warwick chemists have taken out much of the cocoa butter ... with tiny droplets of juice measuring under 30 microns in ... dark and white chocolate using what is known as a ...
Cached Biology News:Researchers identify key culprit causing muscle atrophy 2Researchers identify key culprit causing muscle atrophy 3Chromosomal translocations point the way toward personalized cancer care 2Chromosomal translocations point the way toward personalized cancer care 3Fruity science halves fat in chocolate 2
Homogenizing Solution, 18ml Proteinase K - [50ug/l] 75 l...
Lipofectin Reagent is the reagent of choice for some cell lines; cells of endothelial derivation transfect well with Lipofectin Reagent....
Request Info...
... Clone/PAD: 5B15-5B-11E. Immunogen: Synthetic peptide ... human MUC5B protein. Specificity: Specific ... protein. On Western blots it identifies the ... Human (positive controls: deglycosylated secreted media ...
Biology Products: